European Medicines Agency recommends granting a marketing authorisation for lipegfilgrastim

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product lipegfilgrastim (Lonquex), 6 mg, solution for injection intended for prophylaxis against chemotherapy-induced neutropenia. The active substance of Lonquex is lipegfilgrastim, an immunostimulating medicinal product (L03AA14) which regulates the production and release of functional neutrophils from the bone marrow. Read more here.